GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...